Funder
Guangdong Basic and Applied Basic Research Foundation
Young Teacher Foundation of Sun Yat-sen University
National Key R&D Program of China
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference40 articles.
1. Yokota S (2002) Mizoribine: mode of action and effects in clinical use. Pediatr Int 44(2):196–198. https://doi.org/10.1046/j.1328-8067.2002.01536.x
2. Yuan X, Chen C, Zheng Y, Wang C (2018) Conversion from mycophenolates to mizoribine is associated with lower BK virus load in kidney transplant recipients: a prospective study. Transplant Proc 50(10):3356–3360. https://doi.org/10.1016/j.transproceed.2018.01.059
3. Shi Y, Liu H, Chen XG, Shen ZY (2017) Comparison of mizoribine and mycophenolate mofetil with a tacrolimus-based immunosuppressive regimen in living-donor kidney transplantation recipients: a retrospective study in China. Transplant Proc 49(1):26–31. https://doi.org/10.1016/j.transproceed.2016.10.018
4. Ishida H, Takahara S, Amada N, Tomikawa S, Chikaraishi T, Takahashi K, Uchida K, Akiyama T, Tanabe K, Toma H (2016) A prospective randomized, comparative trial of high-dose mizoribine versus mycophenolate mofetil in combination with tacrolimus and basiliximab for living donor renal transplant: a multicenter trial. Exp Clin Transplant 14(5):518–525
5. Amemiya H, Suzuki S, Watanabe H, Hayashi R, Niiya S (1989) Synergistically enhanced immunosuppressive effect by combined use of cyclosporine and mizoribine. Transplant Proc 21(1 Pt 1):956–958